These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15711834)

  • 1. Atorvastatin does not affect the pharmacokinetics of cyclosporine in renal transplant recipients.
    Hermann M; Asberg A; Christensen H; Reubsaet JL; Holdaas H; Hartmann A
    Eur J Clin Pharmacol; 2005 Mar; 61(1):59-62. PubMed ID: 15711834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients.
    Taylor PJ; Kubler PA; Lynch SV; Allen J; Butler M; Pillans PI
    Ann Pharmacother; 2004 Feb; 38(2):205-8. PubMed ID: 14742751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A.
    Park JW; Siekmeier R; Lattke P; Merz M; Mix C; Schüler S; Jaross W
    J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):351-61. PubMed ID: 11907637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The concentration of cyclosporine metabolites is significantly lower in kidney transplant recipients with diabetes mellitus.
    Akhlaghi F; Dostalek M; Falck P; Mendonza AE; Amundsen R; Gohh RY; Asberg A
    Ther Drug Monit; 2012 Feb; 34(1):38-45. PubMed ID: 22210099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
    Kovarik JM; Kahan BD; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C;
    Clin Pharmacol Ther; 2001 Jan; 69(1):48-56. PubMed ID: 11180038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients.
    Hermann M; Asberg A; Christensen H; Holdaas H; Hartmann A; Reubsaet JL
    Clin Pharmacol Ther; 2004 Oct; 76(4):388-91. PubMed ID: 15470339
    [No Abstract]   [Full Text] [Related]  

  • 7. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients.
    Asberg A; Hartmann A; Fjeldså E; Bergan S; Holdaas H
    Am J Transplant; 2001 Nov; 1(4):382-6. PubMed ID: 12099384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclosporine Metabolites' Metabolic Ratios May Be Markers of Cardiovascular Disease in Kidney Transplant Recipients Treated with Cyclosporine A-Based Immunosuppression Regimens.
    Hryniewiecka E; Żegarska J; Żochowska D; Samborowska E; Jaźwiec R; Kosieradzki M; Nazarewski S; Dadlez M; Pączek L
    Cardiovasc Toxicol; 2019 Jun; 19(3):255-263. PubMed ID: 30471016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects.
    Farid NA; Small DS; Payne CD; Jakubowski JA; Brandt JT; Li YG; Ernest CS; Salazar DE; Konkoy CS; Winters KJ
    Pharmacotherapy; 2008 Dec; 28(12):1483-94. PubMed ID: 19025429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of atorvastatin on the pharmacokinetics of everolimus among kidney transplant recipients.
    Wanitchanont A; Somparn P; Vadcharavivad S; Chancharoenthana W; Townamchai N; Praditpornsilpa K; Avihingsanon Y
    Transplant Proc; 2014; 46(2):418-21. PubMed ID: 24655978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose and steady state pharmacokinetics of CSA and two main primary metabolites, AM1 and AM4n in patients with rheumatic/autoimmune diseases.
    Suchy D; Dostalek M; Perinova I; Brozmanova H; Grundmann M; Vyskocil V; Mayer O
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Sep; 155(3):269-74. PubMed ID: 22286813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significant discrepancy in cyclosporin A post-dose concentrations when analyzed with specific RIA and HPLC method.
    Grundmann M; Perinova I; Brozmanova H; Koristkova B; Safarcik K
    Int J Clin Pharmacol Ther; 2010 Feb; 48(2):87-92. PubMed ID: 20137760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil.
    Choi DH; Shin WG; Choi JS
    Eur J Clin Pharmacol; 2008 May; 64(5):445-9. PubMed ID: 18193210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.
    Cilla DD; Whitfield LR; Gibson DM; Sedman AJ; Posvar EL
    Clin Pharmacol Ther; 1996 Dec; 60(6):687-95. PubMed ID: 8988072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of steady-state atorvastatin on the pharmacokinetics of a single dose of colchicine in healthy adults under fasted conditions.
    Davis MW; Wason S
    Clin Drug Investig; 2014 Apr; 34(4):259-67. PubMed ID: 24452746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective cross-over study comparing the pharmacokinetics of cyclosporine A and its metabolites after oral versus short-time intravenous cyclosporine A administration in pre-heart transplant patients.
    Lehle K; Kirchner GI; Rupprecht L; Gruber M; Birnbaum DE; Schmid FX; Preuner JG
    Transplant Proc; 2007 Dec; 39(10):3323-8. PubMed ID: 18089380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of orange and tangerine juice on cyclosporine levels in renal transplant recipients.
    Sorkhi H; Oliaei F; Moghadamnia AA; Pouramin M; Firoozjahi AR
    Transplant Proc; 2007 May; 39(4):1228-30. PubMed ID: 17524940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients.
    Bauer S; Störmer E; Johne A; Krüger H; Budde K; Neumayer HH; Roots I; Mai I
    Br J Clin Pharmacol; 2003 Feb; 55(2):203-11. PubMed ID: 12580993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP3A5 polymorphism effect on cyclosporine pharmacokinetics in living donor renal transplant recipients: analysis by population pharmacokinetics.
    Song J; Kim MG; Choi B; Han NY; Yun HY; Yoon JH; Oh JM
    Ann Pharmacother; 2012 Sep; 46(9):1141-51. PubMed ID: 22947591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic interaction between levofloxacin and ciclosporin or tacrolimus in kidney transplant recipients: ciclosporin, tacrolimus and levofloxacin in renal transplantation.
    Federico S; Carrano R; Capone D; Gentile A; Palmiero G; Basile V
    Clin Pharmacokinet; 2006; 45(2):169-75. PubMed ID: 16485913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.